Sign In
Buy USNA
USANA Health Sciences Earnings Calls
| Release date | Oct 21, 2025 |
| EPS estimate | $0.250 |
| EPS actual | -$0.150 |
| EPS Surprise | -160.00% |
| Revenue estimate | 219.848M |
| Revenue actual | 213.67M |
| Revenue Surprise | -2.81% |
| Release date | Jul 22, 2025 |
| EPS estimate | $0.540 |
| EPS actual | $0.740 |
| EPS Surprise | 37.04% |
| Revenue estimate | 225.819M |
| Revenue actual | 235.848M |
| Revenue Surprise | 4.44% |
| Release date | Apr 22, 2025 |
| EPS estimate | $0.700 |
| EPS actual | $0.730 |
| EPS Surprise | 4.29% |
| Revenue estimate | 220.371M |
| Revenue actual | 249.539M |
| Revenue Surprise | 13.24% |
| Release date | Feb 25, 2025 |
| EPS estimate | $0.490 |
| EPS actual | $0.640 |
| EPS Surprise | 30.61% |
| Revenue estimate | 208.825M |
| Revenue actual | 213.613M |
| Revenue Surprise | 2.29% |
Last 4 Quarters for USANA Health Sciences
Below you can see how USNA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 25, 2025 |
| Price on release | $31.96 |
| EPS estimate | $0.490 |
| EPS actual | $0.640 |
| EPS surprise | 30.61% |
| Date | Price |
|---|---|
| Feb 19, 2025 | $31.20 |
| Feb 20, 2025 | $32.09 |
| Feb 21, 2025 | $31.78 |
| Feb 24, 2025 | $32.69 |
| Feb 25, 2025 | $31.96 |
| Feb 26, 2025 | $33.21 |
| Feb 27, 2025 | $28.64 |
| Feb 28, 2025 | $29.59 |
| Mar 03, 2025 | $29.98 |
| 4 days before | 2.44% |
| 4 days after | -6.20% |
| On release day | 3.91% |
| Change in period | -3.91% |
| Release date | Apr 22, 2025 |
| Price on release | $24.24 |
| EPS estimate | $0.700 |
| EPS actual | $0.730 |
| EPS surprise | 4.29% |
| Date | Price |
|---|---|
| Apr 15, 2025 | $24.01 |
| Apr 16, 2025 | $23.43 |
| Apr 17, 2025 | $23.74 |
| Apr 21, 2025 | $23.83 |
| Apr 22, 2025 | $24.24 |
| Apr 23, 2025 | $25.43 |
| Apr 24, 2025 | $27.10 |
| Apr 25, 2025 | $27.18 |
| Apr 28, 2025 | $27.54 |
| 4 days before | 0.96% |
| 4 days after | 13.61% |
| On release day | 4.91% |
| Change in period | 14.70% |
| Release date | Jul 22, 2025 |
| Price on release | $31.53 |
| EPS estimate | $0.540 |
| EPS actual | $0.740 |
| EPS surprise | 37.04% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $31.33 |
| Jul 17, 2025 | $30.63 |
| Jul 18, 2025 | $30.35 |
| Jul 21, 2025 | $30.29 |
| Jul 22, 2025 | $31.53 |
| Jul 23, 2025 | $35.43 |
| Jul 24, 2025 | $32.09 |
| Jul 25, 2025 | $31.95 |
| Jul 28, 2025 | $31.44 |
| 4 days before | 0.638% |
| 4 days after | -0.285% |
| On release day | 12.37% |
| Change in period | 0.351% |
| Release date | Oct 21, 2025 |
| Price on release | $21.03 |
| EPS estimate | $0.250 |
| EPS actual | -$0.150 |
| EPS surprise | -160.00% |
| Date | Price |
|---|---|
| Oct 15, 2025 | $20.51 |
| Oct 16, 2025 | $21.07 |
| Oct 17, 2025 | $20.89 |
| Oct 20, 2025 | $20.68 |
| Oct 21, 2025 | $21.03 |
| Oct 22, 2025 | $20.91 |
| Oct 23, 2025 | $20.63 |
| Oct 24, 2025 | $20.80 |
| Oct 27, 2025 | $20.10 |
| 4 days before | 2.54% |
| 4 days after | -4.42% |
| On release day | -0.571% |
| Change in period | -2.00% |
USANA Health Sciences Earnings Call Transcript Summary of Q3 2025
USANA reported softer third-quarter results driven by near-term uptake and Brand Partner productivity ahead of its Global Convention and the global rollout of an enhanced compensation plan. Management believes the new plan—focused on simplicity, early earnings and pay-for-performance—has begun to drive renewed engagement, improved meeting attendance, faster speed-to-first-commission and reactivation of longer-tenured Brand Partners, with initial sales lift observed in September and early October. Inventories rose due to new product introductions, tariff-mitigation positioning and working capital for venture businesses Hiya and Rise Bar. Hiya delivered 26% year-to-date sales growth despite Q3 top-line headwinds tied to platform algorithm changes; further integration (ERP, logistics, and planned in-house manufacturing) is expected to drive margin improvement in late Q2/H2 FY2026. Rise Bar posted record Q3 sales and 169% year-to-date growth. Management has launched a global cost-reduction and rightsizing program and expects a one-time charge of approximately $4.7 million in Q4; details and expected run-rate savings will be provided later (management indicated more commentary in February). The company remains committed to its direct-selling core while pursuing diversification via DTC and healthy-food ventures and selective M&A as capital allows.
